<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="31%"></col>
<col width="34%"></col>
<col width="41%"></col>
<tbody>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Drug/Drug Class (Mechanism of Interaction by Voriconazole) </content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Drug Plasma Exposure <br/>(C<sub>max</sub> and AUCτ)</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Recommendations for Drug Dosage Adjustment/Comments</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Sirolimus* <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Rifabutin*<br/> (CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Efavirenz (400 mg q 24h)** <br/>(CYP3A4 Inhibition) </paragraph>
<paragraph>Efavirenz (300 mg q 24h) **</paragraph>
<paragraph>(CYP3A4 Inhibition)</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
<paragraph>Slight decrease in AUC<sub>t</sub>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
<paragraph>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>High-dose Ritonavir (400 mg q12h)**(CYP3A4 Inhibition)</paragraph>
<paragraph>Low-dose Ritonavir (100 mg q12h)** </paragraph>
</td>
<td rowspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>No Significant Effect of Voriconazole on</paragraph>
<paragraph>Ritonavir C<sub>max</sub> or AUCτ</paragraph>
<paragraph>Slight Decrease in Ritonavir C<sub>max</sub> and AUCτ</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated </content>because of significant reduction of voriconazole C<sub>max</sub> and AUCτ  </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided (due to the reduction in voriconazole C<sub>max</sub> and AUCτ) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Terfenadine, Astemizole, Cisapride, Pimozide, Quinidine (CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated</content> because of potential for QT prolongation and rare occurrence of torsade de pointes </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Ergot Alkaloids<br/>(CYP450 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Cyclosporine* <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>AUCτ Significantly Increased; No Significant Effect on C<sub>max</sub>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>When initiating therapy with voriconazole in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When voriconazole is discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Methadone*** <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Fentanyl <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole. Extended and frequent monitoring for opiate-associated adverse events may be necessary [see DRUG INTERACTIONS (7)] </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Alfentanil <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole. A longer period for monitoring respiratory and other opiate-associated adverse events may be necessary [see DRUG INTERACTIONS (7)]. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Oxycodone <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole. Extended and frequent monitoring for opiate-associated adverse events may be necessary [see DRUG INTERACTIONS (7)].</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>NSAIDs**** including ibuprofen and diclofenac</paragraph>
<paragraph>(CYP2C9 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed. [see DRUG INTERACTIONS (7)].</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Tacrolimus* </paragraph>
<paragraph>(CYP3A4 Inhibition)</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>When initiating therapy with voriconazole in patients already receiving tacrolimus, reduce the tacrolimus dose to one-third of the starting dose and follow with frequent monitoring of tacrolimus blood levels. Increased tacrolimus levels have been associated with nephrotoxicity. When voriconazole is discontinued, tacrolimus concentrations must be frequently monitored and the dose increased as necessary.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Phenytoin* </paragraph>
<paragraph>(CYP2C9 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring of phenytoin plasma concentrations and frequent monitoring of adverse effects related to phenytoin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP3A4 Inhibition)** </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Monitoring for adverse events related to oral contraceptives is recommended during coadministration.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Warfarin* </paragraph>
<paragraph>(CYP2C9 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Prothrombin Time Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Monitor PT or other suitable anticoagulation tests. Adjustment of warfarin dosage may be needed.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Omeprazole*</paragraph>
<paragraph>(CYP2C19/3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>When initiating therapy with voriconazole in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half. The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Other HIV Protease Inhibitors </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant </paragraph>
<paragraph>Effects on Indinavir Exposure</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>No dosage adjustment for indinavir</paragraph>
<paragraph>when coadministered with voriconazole tablets</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity related to other HIV protease inhibitors</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Other NNRTIs*****</paragraph>
<paragraph> (CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for Voriconazole to Inhibit Metabolism of Other NNRTIs </paragraph>
<paragraph>(Increased Plasma Exposure) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity related to NNRTI</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Benzodiazepines </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity (i.e., prolonged sedation) related to benzodiazepines metabolized by CYP3A4 (e.g., midazolam, triazolam, alprazolam). Adjustment of benzodiazepine dosage may be needed.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>HMG-CoA Reductase Inhibitors (Statins) (CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity related to statins. Increased statin concentrations in plasma have been associated with rhabdomyolysis. Adjustment of the statin dosage may be needed.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Dihydropyridine Calcium Channel Blockers </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. Adjustment of oral hypoglycemic drug dosage may be needed. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule         Lrule          Rrule     " valign="top"> <paragraph>Vinca Alkaloids </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Frequent monitoring for adverse events and toxicity (i.e., neurotoxicity) related to vinca alkaloids. Adjustment of vinca alkaloid dosage may be needed. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Everolimus</paragraph>
<paragraph>(CYP3A4 Inhibition)</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Not Studied  <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> <paragraph>Concomitant administration of</paragraph>
<paragraph>voriconazole and everolimus is not recommended</paragraph>
</td>
</tr>
</tbody>
</table>